WO2026008069 - USE OF CYTOKINE ANTAGONIST IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING CRS
National phase entry is expected:
Publication Number
WO/2026/008069
Publication Date
08.01.2026
International Application No.
PCT/CN2025/107171
International Filing Date
04.07.2025
Title **
[English]
USE OF CYTOKINE ANTAGONIST IN PREPARATION OF DRUG FOR PREVENTING AND/OR TREATING CRS
[French]
UTILISATION D'UN ANTAGONISTE DE CYTOKINE DANS LA PRÉPARATION D'UN MÉDICAMENT POUR LA PRÉVENTION ET/OU LE TRAITEMENT DU SLC
[Chinese]
细胞因子拮抗剂在制备预防和/或治疗CRS的药物中的应用
Applicants **
SHENZHEN GENOCURY BIOTECH CO., LTD
Inventors
HUANG, Ke
LI, Yuhang
Priority Data
202410900679.3
05.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1768 | |
| EPO | Filing, Examination, Granting | 12091 | |
| Japan | Filing, Examination, Granting | 2108 | |
| South Korea | Filing, Examination, Granting | 1984 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,691
Contact Us
Abstract[English]
The present invention relates to the field of cell therapies, and in particular to use of a cytokine antagonist in the preparation of a drug for preventing and/or treating death from CRS. Disclosed is use of a cytokine antagonist in the preparation of a drug for preventing and/or treating death from CRS, the cytokine antagonist being a TNFα antagonist.[French]
La présente invention concerne le domaine des thérapies cellulaires, et en particulier l'utilisation d'un antagoniste de cytokine dans la préparation d'un médicament pour la prévention et/ou le traitement de la mort causée par le SLC. L'invention concerne l'utilisation d'un antagoniste de cytokine dans la préparation d'un médicament pour la prévention et/ou le traitement de la mort causée par le SLC, l'antagoniste de cytokine étant un antagoniste de TNFα.[Chinese]
涉及细胞疗法领域，具体涉及细胞因子拮抗剂在制备预防和/或治疗CRS致死的药物中的应用。公开了细胞因子拮抗剂在制备预防和/或治疗CRS致死的药物中的应用，所述细胞因子拮抗剂是TNFα拮抗剂。